CC 24999/2024

May 3, 2024·EP3536712 · METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

Case details: Status
Case Closed (Patent upheld as granted)
Action
Counterclaim for revocation
Category
Counterclaim for revocation
Parties: Claimants
Amgen S.R.L.Operating co.
Representatives
Johannes Heselberger-Bardehle Pagenberg
Nadine Westermeyer-Bardehle Pagenberg
Respondents
Regeneron Pharmaceuticals Inc.Operating co.
Representatives
Niels Hoelder-Hoffmann Eitle
Mike Gruber-Hoffmann Eitle
Michael Pfeifer-Hoffmann Eitle
Daniel Wise-Carpmaels & Ransford
Agathe Michel-De Cazotte-Carpmaels & Ransford
Division: Dusseldorf LD
Judges: Ronny Thomas
Berenice Thom
András Kupecz
Xavier Dorland-Galliot
Technology: Chemistry
Biotechnology · Pharmaceuticals
Language: English
EPO Opposition: Amgen Inc.Withdrawn2024-02-29

How this compares

The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.

	Patent revoked	Median days to first decision
All UPC	37% (34/91)	124
Dusseldorf LD	Locked	Locked
Judge Ronny Thomas	Locked	Locked
Judge Berenice Thom	Locked	Locked
Judge András Kupecz	Locked	Locked
Judge Xavier Dorland-Galliot	Locked	Locked

Related cases

Decisions

—
revocation counterclaim
Summary: I. The infringement action is dismissed. II. The counterclaim for revocation is dismissed. III. The costs of the infringement action shall be borne by the Claimants in equal shares.

Documents